solitomab solitomab solitomab (inn; development code mt110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. it is a fusion protein consisting of two single-chain variable fragments (scfvs) of different antibodies on a single peptide chain of about 55 kilodaltons. one of the scfvs binds to t cells via the cd3 receptor, and the other to epcam as a tumor antigen against gastrointestinal, lung, and other cancers. solitomabmonoclonal antibodytypebi-specific t-cell engagersourcemousetargetepcamclinical dataatc codenoneidentifierscas number1005198-65-1chemspidernoneuniizqq51b5708 mechanism of action a bite linking a t cell to a tumor cell. like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between t cells and its target tumor cell antigen. this causes t cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of mhc i or co-stimulatory molecules. these proteins enter tumor cells and initiate the cell's apoptosis. this action mimics physiological processes observed during t cell attacks against tumor cells.